Cerep Grants BioPrint® Access to AstraZeneca
News May 12, 2006
Through this alliance, AstraZeneca will have non-exclusive access to physicochemical, pharmacological and clinical data on BioPrint® compounds as well as to BioPrint® informatics tools to support internal drug discovery and development.
Payment of the license fee has been recognized upon acceptance of the data and IT tools delivered by Cerep in the first quarter 2006.
"We are very happy to announce this alliance with AstraZeneca," commented Mark Crawford, Executive Vice President for Cerep.
"BioPrint® has been established in the industry as an extremely useful tool to support drug discovery and drug development."
"We are particularly proud to have the value of BioPrint® recognized by AstraZeneca."
"We believe that database-supported pharmaco-informatics can play an important role in expediting drug discovery. We have been pleased with Cerep's BioPrint® database and we look forward to implementing this tool at AstraZeneca," commented Tim Hammond, Vice President of Safety Assessment UK, for AstraZeneca.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE